

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Spiramycin Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-  
stance/Mixture : Veterinary product

Recommended restrictions  
on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Kilsheelan  
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person  
responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2	H319: Causes serious eye irritation.
Skin sensitisation, Category 1	H317: May cause an allergic skin reaction.
Reproductive toxicity, Category 1B	H360FD: May damage fertility. May damage the unborn child.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H317 May cause an allergic skin reaction.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

H319 Causes serious eye irritation.  
H360FD May damage fertility. May damage the unborn child.

Precautionary statements

:

**Prevention:**

P201 Obtain special instructions before use.  
P264 Wash skin thoroughly after handling.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.  
P337 + P313 If eye irritation persists: Get medical advice/ attention.

Hazardous components which must be listed on the label:

2-Pyrrolidone  
Benzyl alcohol

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

**Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
2-Pyrrolidone	616-45-5 210-483-1	Eye Irrit. 2; H319 Repr. 1B; H360FD specific concentra- tion limit	>= 30 - < 50

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

		Repr. 1B; H360FD > 3 %	
Benzyl alcohol	100-51-6 202-859-9 603-057-00-5	Acute Tox. 4; H302 Eye Irrit. 2; H319 Skin Sens. 1B; H317  Acute toxicity esti- mate  Acute oral toxicity: 1.200 mg/kg	>= 1 - < 10
Spiramycin	8025-81-8 232-429-6		< 0,1

For explanation of abbreviations see section 16.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version 3.0	Revision Date: 14.04.2025	SDS Number: 7979081-00014	Date of last issue: 28.09.2024 Date of first issue: 19.03.2021
----------------	------------------------------	------------------------------	---

Risks	: May cause an allergic skin reaction. Causes serious eye irritation. May damage fertility. May damage the unborn child.
-------	--

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment	: Treat symptomatically and supportively.
-----------	---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
------------------------------	--

Unsuitable extinguishing media	: None known.
--------------------------------	---------------

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
---------------------------------------	--

Hazardous combustion products	: Nitrogen oxides (NO <sub>x</sub> ) Carbon oxides
-------------------------------	---

### 5.3 Advice for firefighters

Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
----------------------	--

### 6.2 Environmental precautions

Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers).
---------------------------	---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

---

Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Avoid breathing mist or vapours.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

---

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Spiramycin	8025-81-8	TWA	1000 ug/m3 (OEB 1)	Internal

#### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
2-Pyrrolidone	Workers	Inhalation	Long-term systemic effects	57,8 mg/m3
	Workers	Skin contact	Long-term systemic effects	10 mg/kg bw/day
	Workers	Skin contact	Acute systemic effects	277 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	17,1 mg/m3
	Consumers	Skin contact	Long-term systemic effects	6 mg/kg bw/day
	Consumers	Skin contact	Acute systemic effects	167 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	5,2 mg/kg bw/day
	Consumers	Ingestion	Acute systemic effects	33,3 mg/kg bw/day
Benzyl alcohol	Workers	Inhalation	Long-term systemic effects	22 mg/m3
	Workers	Inhalation	Acute systemic effects	110 mg/m3
	Workers	Skin contact	Long-term systemic effects	8 mg/kg bw/day

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

	Workers	Skin contact	Acute systemic effects	40 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	5,4 mg/m3
	Consumers	Inhalation	Acute systemic effects	27 mg/m3
	Consumers	Skin contact	Long-term systemic effects	4 mg/kg bw/day
	Consumers	Skin contact	Acute systemic effects	20 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	4 mg/kg bw/day
	Consumers	Ingestion	Acute systemic effects	20 mg/kg bw/day

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
2-Pyrrolidone	Fresh water	0,5 mg/l
	Freshwater - intermittent	0,5 mg/l
	Marine water	0,05 mg/l
	Sewage treatment plant	10 mg/l
	Fresh water sediment	0,4205 mg/kg dry weight (d.w.)
	Soil	0,0612 mg/kg dry weight (d.w.)
Benzyl alcohol	Fresh water	1 mg/l
	Marine water	0,1 mg/l
	Intermittent use/release	2,3 mg/l
	Sewage treatment plant	39 mg/l
	Fresh water sediment	5,27 mg/kg
	Marine sediment	0,527 mg/kg
	Soil	0,456 mg/kg

## 8.2 Exposure controls

### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection  
Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024  
3.0 14.04.2025 7979081-00014 Date of first issue: 19.03.2021

Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Filter should conform to NS EN 14387
Filter type	: Organic vapour type (A)

## **SECTION 9: Physical and chemical properties**

## 9.1 Information on basic physical and chemical properties

Physical state	:	Aqueous solution
Colour	:	light yellow
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
pH	:	8,0 - 10,0
Viscosity	:	No data available
Viscosity, kinematic	:	No data available
Solubility(ies)	:	No data available
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version 3.0	Revision Date: 14.04.2025	SDS Number: 7979081-00014	Date of last issue: 28.09.2024 Date of first issue: 19.03.2021
----------------	------------------------------	------------------------------	---

Vapour pressure	:	No data available
Relative density	:	No data available
Density	:	0,950 - 1,150 g/cm <sup>3</sup>
Relative vapour density	:	No data available
Particle characteristics		
Particle size	:	Not applicable

### 9.2 Other information

Explosives	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Evaporation rate	:	No data available
Molecular weight	:	No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

### Acute toxicity

||| Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg  
Method: Calculation method

#### Components:

##### **2-Pyrrolidone:**

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
Method: OECD Test Guideline 401  
Assessment: The substance or mixture has no acute oral toxicity

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

##### **Benzyl alcohol:**

Acute oral toxicity : LD50 (Rat): 1.200 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,4 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403  
Assessment: The substance or mixture has no acute inhalation toxicity

##### **Spiramycin:**

Acute oral toxicity : LD50 (Mouse, adult): 2.900 mg/kg  
LD50 (Rat, adult): 3.550 mg/kg  
LD50 (Dog, adult): 5.200 mg/kg  
LD50 (Rabbit, adult): 4.300 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Mouse): 130 mg/kg  
Application Route: Intravenous  
LD50 (Rat): 170 mg/kg  
Application Route: Intravenous  
LD50 (Rabbit): 182 mg/kg  
Application Route: Intravenous

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

---

### Skin corrosion/irritation

||| Not classified based on available information.

#### Components:

##### 2-Pyrrolidone:

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	No skin irritation

##### Benzyl alcohol:

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	No skin irritation

### Serious eye damage/eye irritation

||| Causes serious eye irritation.

#### Components:

##### 2-Pyrrolidone:

Species	:	Rabbit
Result	:	Irritation to eyes, reversing within 7 days

##### Benzyl alcohol:

Species	:	Rabbit
Method	:	OECD Test Guideline 405
Result	:	Irritation to eyes, reversing within 21 days

### Respiratory or skin sensitisation

#### Skin sensitisation

||| May cause an allergic skin reaction.

#### Respiratory sensitisation

||| Not classified based on available information.

#### Components:

##### 2-Pyrrolidone:

Test Type	:	Local lymph node assay (LLNA)
Exposure routes	:	Skin contact
Species	:	Mouse
Method	:	OECD Test Guideline 429
Result	:	negative
Remarks	:	Based on data from similar materials

##### Benzyl alcohol:

Test Type	:	Human repeat insult patch test (HRIPT)
Exposure routes	:	Skin contact
Species	:	Humans

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 7979081-00014      Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

---

||| Result : positive  
||| Assessment : Probability or evidence of low to moderate skin sensitisation rate in humans

### **Spiramycin:**

||| Test Type : Magnusson-Kligman-Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : Not a skin sensitizer.

### **Germ cell mutagenicity**

||| Not classified based on available information.

### **Components:**

#### **2-Pyrrolidone:**

||| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476  
Result: negative  
Remarks: Based on data from similar materials  
  
Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
  
Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Method: OECD Test Guideline 474  
Result: negative

#### **Benzyl alcohol:**

||| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

#### **Spiramycin:**

||| Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster ovary cells  
Result: negative

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

---



Test Type: Cytogenetic assay  
Test system: Chinese hamster ovary cells  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Mouse  
Result: negative

### Carcinogenicity

|| Not classified based on available information.

### Components:

#### 2-Pyrrolidone:

Species	:	Mouse
Application Route	:	Ingestion
Exposure time	:	18 month(s)
Result	:	negative
Remarks	:	Based on data from similar materials

#### Benzyl alcohol:

Species	:	Mouse
Application Route	:	Ingestion
Exposure time	:	103 weeks
Method	:	OECD Test Guideline 451
Result	:	negative

#### Spiramycin:

Species	:	Rat, male and female
Application Route	:	Oral
Exposure time	:	2 Years
Result	:	negative

### Reproductive toxicity

|| May damage fertility. May damage the unborn child.

### Components:

#### 2-Pyrrolidone:

Effects on fertility	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: positive Remarks: Based on data from similar materials
----------------------	---	--

#### Effects on foetal development

Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: positive
-------------------------------	---	--

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 7979081-00014      Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

---

**Reproductive toxicity - Assessment** : Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

### **Benzyl alcohol:**

**Effects on fertility** : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**Effects on foetal development** : Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Ingestion  
Result: negative

### **Spiramycin:**

**Effects on fertility** : Test Type: Fertility  
Species: Rat, male  
Target Organs: Reproductive organs  
Result: alteration in sperm morphology, Effects on male reproductive organs

**Effects on foetal development** : Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
General Toxicity Maternal: 100 mg/kg body weight  
Developmental Toxicity: LOAEL: 200 mg/kg body weight  
Embryo-foetal toxicity: LOAEL: 200 mg/kg body weight

### **STOT - single exposure**

Not classified based on available information.

### **STOT - repeated exposure**

Not classified based on available information.

### **Repeated dose toxicity**

#### **Components:**

##### **2-Pyrrolidone:**

Species : Rat  
NOAEL : 207 mg/kg  
Application Route : Ingestion  
Exposure time : 3 Months  
Method : OECD Test Guideline 408

##### **Benzyl alcohol:**

Species : Rat  
NOAEL : 1,072 mg/l  
Application Route : inhalation (dust/mist/fume)

## SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024  
3.0 14.04.2025 7979081-00014 Date of first issue: 19.03.2021

Exposure time : 28 Days  
Method : OECD Test Guideline 412

## **Spiramycin:**

Species	: Rat, male and female
NOAEL	: 140 mg/kg
Application Route	: Oral
Exposure time	: 13 Weeks
Target Organs	: Immune system

Species	: Rat, male and female
LOAEL	: 5,6 mg/kg
Application Route	: Intravenous
Exposure time	: 32 d
Target Organs	: Central nervous system

Species	: Dog, male and female
NOAEL	: 75 mg/kg
Application Route	: Oral
Exposure time	: 2 yr
Target Organs	: Kidney, male reproductive organs, optic nerve

Species	: Dog, male and female
LOAEL	: 169 mg/kg
Application Route	: Intravenous
Exposure time	: 4 Weeks
Number of exposures	: 2 injections per day
Target Organs	: spleen, Kidney

Species	: Dog, male and female
LOAEL	: 50 mg/kg
Application Route	: Intravenous
Exposure time	: 4 Weeks
Target Organs	: Central nervous system

## Aspiration toxicity

Not classified based on available information

## 11.2 Information on other hazards

## Endocrine disrupting properties

Not classified based on available information.

### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

---

### Experience with human exposure

#### Components:

##### **Spiramycin:**

General Information : May cause  
Symptoms: Nausea, Vomiting, Diarrhoea

#### Further information

#### Components:

##### **Spiramycin:**

Remarks : No data available

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### **2-Pyrrolidone:**

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 4.600 - 10.000 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 500 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): > 500 mg/l  
Exposure time: 72 h  
EC10 (Desmodesmus subspicatus (green algae)): 22,2 mg/l  
Exposure time: 72 h

Toxicity to microorganisms : EC50 : > 1.000 mg/l  
Exposure time: 30 min  
Method: OECD Test Guideline 209

##### **Benzyl alcohol:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 460 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 230 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 770 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 7979081-00014      Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

---

		NOEC (Pseudokirchneriella subcapitata (green algae)): 310 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 51 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

### 12.2 Persistence and degradability

#### Components:

##### **2-Pyrrolidone:**

Biodegradability	:	Result: Readily biodegradable. Remarks: Based on data from similar materials
------------------	---	---

##### **Benzyl alcohol:**

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 92 - 96 % Exposure time: 14 d
------------------	---	--

### 12.3 Bioaccumulative potential

#### Components:

##### **2-Pyrrolidone:**

Partition coefficient: n-octanol/water	:	log Pow: -0,71 Method: OECD Test Guideline 107
--	---	---

##### **Benzyl alcohol:**

Partition coefficient: n-octanol/water	:	log Pow: 1,05
--	---	---------------

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment	:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
------------	---	--

### 12.6 Endocrine disrupting properties

#### Product:

Assessment	:	The substance/mixture does not contain components considered to have endocrine disrupting properties according to
------------	---	---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

---

REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number or ID number

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

### 14.2 UN proper shipping name

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version 3.0	Revision Date: 14.04.2025	SDS Number: 7979081-00014	Date of last issue: 28.09.2024 Date of first issue: 19.03.2021
----------------	------------------------------	------------------------------	---

### 14.4 Packing group

<b>ADN</b>	:	Not regulated as a dangerous good
<b>ADR</b>	:	Not regulated as a dangerous good
<b>RID</b>	:	Not regulated as a dangerous good
<b>IMDG</b>	:	Not regulated as a dangerous good
<b>IATA (Cargo)</b>	:	Not regulated as a dangerous good
<b>IATA (Passenger)</b>	:	Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

: Conditions of restriction for the following entries should be considered: Number on list 3

Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).

: Not applicable

REACH - List of substances subject to authorisation (Annex XIV)

: Not applicable

Regulation (EU) No 2024/590 on substances that deplete the ozone layer

: Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast)

: Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

: Not applicable

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

---

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

### Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

---

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H302 : Harmful if swallowed.  
H317 : May cause an allergic skin reaction.  
H319 : Causes serious eye irritation.  
H360FD : May damage fertility. May damage the unborn child.

### Full text of other abbreviations

Acute Tox. : Acute toxicity  
Eye Irrit. : Eye irritation  
Repr. : Reproductive toxicity  
Skin Sens. : Skin sensitisation

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships car-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Spiramycin Formulation

Version  
3.0

Revision Date:  
14.04.2025

SDS Number:  
7979081-00014

Date of last issue: 28.09.2024  
Date of first issue: 19.03.2021

rying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Eye Irrit. 2	H319
Skin Sens. 1	H317
Repr. 1B	H360FD

### Classification procedure:

Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN